Tempus AI
Valuation each multiple against its own 5-year range
Vs. peers Health Information Services
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Tempus AI (TEM) | 9.86B | -50.98 | 19.70 | 0.00% |
| Veeva Systems (VEEV) | 43.10B | 43.64 | 5.80 | 0.00% |
| BrightSpring Health Services (BTSG) | 12.50B | 33.78 | 5.75 | 0.00% |
| Hinge Health (HNGE) | 8.60B | 51.68 | 28.71 | 0.00% |
| HealthEquity (HQY) | 7.84B | 34.21 | 3.94 | 0.00% |
| Doximity (DOCS) | 5.13B | 39.90 | 5.52 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 18.6% below Morningstar's fair value estimate.
Fair value
Tempus AI Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 7% discount to our quantitative fair value estimate of $64.09 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The firm's balance sheet bolsters our valuation estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of -1.0, which sits in the bottom 20% compared with global peers. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be undervalued.
On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's enterprise value to free cash flow ratio of 311.5, a core component of profitability, sits in the top 10% compared with peers globally. This suggests limited cash flow is available for reinvestment or return to shareholders, which, despite our favorable price/fair value ratio, is a negative attribute.
Economic moat
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.
Tempus AI discussion 0 comments